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Editorial
Targeting abnormal calcium (Ca)2+ handling in ventricu-lar cardiomyocytes emerged as a new paradigm for hu-
man heart failure (HF) therapy.1 Cardiomyocytes come with 
an extensive Ca2+ signaling toolkit consisting of various Ca2+ 
transporters, Ca2+ channels, Ca2+ buffer, and sensor proteins. 
Organized into self-contained signaling modules in which 
Ca2+ signaling functions within highly localized environ-
ments, the cardiac Ca2+ signalosome delivers dynamic signals 
with different spatial and temporal properties that relay com-
partmentalized Ca2+ oscillations into specific cellular func-
tions.2 As a result, Ca2+ governs not only the cardiomyocyte 
contractile cycle, but also concurrently control transcription 
and muscle growth, electric excitability, cell survival, and 
 energy metabolism.3
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Key components of the cardiac Ca2+ signalosome remodel 
as a molecular hallmark in HF: loss of sarco(endo)plasmic 
reticulum ATPase 2a (SERCA2a) expression surfaced as 1 
critical abnormality in experimental HF and human failing 
myocardium. The defect alone is sufficient to disable vari-
ous Ca2+-dependent homeostatic mechanisms that drive fur-
ther deterioration of cardiac function and structure after a 
primary insult, such as myocardial infarction.1 Translational 
studies, particularly in human-relevant large animal models, 
have successfully used recombinant adeno-associated viral 
(rAAV) vectors for cardiac- targeted delivery of therapeuti-
cally formulated synthetic SERCA2a DNA that resulted in 
safe and long-term restoration of cardiac function and rever-
sal of structural, electric, and metabolic remodeling in ex-
perimental HF.4 Hence, targeting defective components of the 
cardiomyocyte Ca2+ signalosome in HF might bear therapeu-
tic benefits beyond sole improvement of cardiac contractile 
performance (Figure).
The Calcium Up-regulation by Percutaneous Administration 
of Gene Therapy In Cardiac Disease (CUPID) trial is the first 
translation of this concept into clinically reality. Intracoronary 
infusion of an rAAV serotype 1 (rAAV1) carrying the human 
SERCA2a gene under control of a ubiquitous cytomegalovi-
rus promoter (AAV1-cytomegalovirus-SERCA2a) is meant 
to replenish diminished SERCA2a protein levels in hearts of 
patients with New York Heart Association (NYHA) stage II/
III HF (http://clinicaltrials.gov; NCT00454818). To date, this 
trial epitomizes the quest for novel molecular-targeted HF 
treatments that could improve conventional clinical regimes, 
which cannot target underlying molecular defects in failing 
cardiomyocytes. At the same time, it blazes new regulatory 
trails for advanced molecular cardiovascular therapies; an ex-
perience that is expected to greatly benefit future DNA-based 
therapeutic developments against human HF.1
In this issue of Circulation Research, Zsebo et al5 re-
port on the 36-month follow-up of 39 patients enrolled in 
CUPID trial phase IIa, which is a randomized, double-blind, 
 placebo-controlled, dose-ranging study. This report advances 
previously published data on a 12-month active observation 
period6 by additional 24-month follow-up, this time using 
nonadjudicated patient self-reported history. During the sec-
ond and third year of follow-up, patients were contacted every 
6 months by the healthcare provider for a structured question-
naire on health status.
Most importantly, the study reports no apparent adverse events 
in patients with HF potentially related to the long-term treatment 
with increasing dosages of rAAV1-cytomegalovirus- SERCA2a. 
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Figure. Calcium (Ca)2+ regulation of cardiomyocyte function 
is not limited to contractile performance but extends to 
control over nuclear transcription, electric activity, cell 
survival, and energy metabolism. Targeting key components 
of the defective Ca2+ signalosome inside failing cardiomyocytes 
using recombinant adeno-associated viral–based therapeutic 
formulations of DNA bears the promise to achieve sustained 
therapeutic efficacy beyond improvement of cardiac performance.
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From an immunologic point of view, this is noteworthy, be-
cause studies using  rAAV-based therapeutic formulations have 
progressed from rodent models to clinical trials (see http://
www.abedia.com/wiley/vectors.php for continuous update). 
From this, we have learned that immune responses after rAAV 
gene delivery occur more readily in larger animal models 
and in humans.7 Potential immune responses are transgene 
specific and influenced by ways of administration, choice of 
rAAV serotypes, as well as dosage, transgene expression lev-
els, and expression control elements. Hence, long-term safety 
of  rAAV1-cytomegalovirus-SERCA2a in humans cannot be 
taken for granted, particularly, because initial attempts at viral 
vector-based human gene therapy using retro- or adenovirus-
es in other fields have been met with issues of toxicity, either 
through activation of immunity or genomic integration and tu-
mor formation.8
Unlike adenoviruses, in vivo use of rAAVs entails only 
transient induction of cytokines in target cells and, in addi-
tion, shows inefficient transduction of antigen- presenting 
cells. Subsequent lack of major histocompatability com-
plex I–mediated direct transgene presentation may allow 
rAAVs to evade the generation of a cytotoxic T-cell response; 
a mechanism likely contributing to rAAV-mediated long-term 
transgene expression.7,8 Importantly, the use of ubiquitously 
active promoters, which can result in high off-target transgene 
 expression in tissues other than the targeted organ, has been 
reported to drive transgene expression in antigen-presenting 
cells enabling major histocompatability complex I–mediated 
direct transgene presentation and development of transgene- 
specific immunity over time.9 In addition, combined use of an 
rAAV serotype that readily transduces tissues other than the 
targeted organ can enhance the risk of triggering cellular im-
munity.7 In this regard, the encouraging 3-year safety profile 
of the rAAV1-cytomegalovirus-SERCA2a formulation is an 
important finding at this early stage of clinical testing where 
safety is embedded to serve as stopping rule. This result paves 
the way to phase IIb of the CUPID trial aimed at enrolling 200 
patients with HF.
With respect to efficacy and statistical power, a phase IIa 
clinical trial generally presents special difficulties because it 
involves the use of a therapeutic agent in a small patient pop-
ulation whose likelihood of benefit and effect size is poorly 
understood. To address this issue, a statistical method (joint 
frailty model) of concordant changes in clinical end points 
for group- and individual-level comparisons and outcome 
at 6 months for rAAV1-cytomegalovirus-SERCA2a treat-
ment was used in a previous report to determine predefined 
meaningful changes in the CUPID phase IIa patient popu-
lation.6 Now, Zsebo et al5 report a promising lower 3-year 
cumulative and cardiovascular clinical event rate, including 
decreased hospitalization and improved survival in the high-
dose  rAAV1-cytomegalovirus-SERCA2a group. Because 
these positive results are based on nonadjudicated patient 
self-reported history and small patient numbers, more conven-
tional statistical analysis and larger patient populations at the 
end are actually needed to assess clinical efficacy. Because 
of the promising trends seen in phase IIa,6 phase IIb is ex-
pected to establish evidence of therapeutic efficacy of rAAV1-
cytomegalovirus-SERCA2 in human HF on top of standard 
therapy eventually. As part of the study protocol, it will deliver 
relevant functional and clinical end points such as 6-month 
changes in left ventricular ejection fraction and peak oxygen 
consumption, as well as all-cause mortality and hospitaliza-
tion rate adjudicated by a clinical end point committee.
The authors further provide first information on 
 rAAV1-cytomegalovirus-SERCA2a transgene persistence 
in explanted hearts of patients with HF5 who eventually un-
derwent transplantation, required placement of a ventricular 
assist device, or died. Quantitative polymerase chain reac-
tion analysis was used to detect SERCA2a DNA copies with 
positive results in the high-dosage group up to month 31 after 
treatment but not in the placebo, low-dose, or in mid-dose 
rAAV1-cytomegalovirus-SERCA2a–treated patients. This 
is another encouraging finding indicating successful trans-
duction of failing myocardium by intracoronary infusion 
of the therapeutic vector in combination with nitro-glycer-
ine to enhance delivery efficacy.5 As previous studies have 
shown that rAAV1 can transduce both cardiomyocytes and 
noncardiomyocytes,10 it would be desirable to determine 
whether myocardial transgene persistence at this point has 
actually resulted in elevated SERCA2a expression levels in 
the  high-dose rAAV1-cytomegalovirus-SERCA2a treatment 
group. In this regard, phase IIb of the CUPID trial might pro-
vide access to more patient samples potentially enabling as-
sessment of myocardial SERCA2a mRNA expression levels 
in placebo and treatment groups.
Overall, the authors are to be congratulated for their out-
standing achievement. It is the first gene-based therapy against 
HF being developed in a basic science laboratory that eventu-
ally entered clinical testing. Hajjar et al4–6 came a long way 
and mastered numerous regulatory hurdles not to mention 
other challenges, including scalability and establishing clini-
cal feasibility of the therapeutic approach. Now, CUPID phase 
IIb is both expected and needed to bring the necessary break-
through to establish clinical efficacy of a novel therapeutic 
principle targeting the defective cardiac Ca2+ signalosome.
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